Project Grant R21DA061372
- Project Grant Summary Massachusetts Institute of Technology received a $1.65 million project grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded on July 15, 2025, with an anticipated completion date of March 31, 2030. The project, titled "Integration and Validation of Single-Cell Neuronal and Immune Molecular Responses in SUD and HIV," delivers advanced computational research analyzing genetic and molecular mechanisms...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded J. David Gladstone Institutes a $1,343,271 Project Grant (CFDA 93.279, Drug Use and Addiction Research Programs) effective May 15, 2025, through March 31, 2030, to develop targeted small molecule recruitment strategies for suppressing the HIV transcriptionally active reservoir in individuals with substance use disorder (SUD). The research addresses a critical gap in antiretroviral therapy (ART), which fails to target latent...
- Federal Project Grant Award Summary Boston Medical Center Corporation received a $356,630 Project Grant from the National Institute on Drug Abuse (Drug Use and Addiction Research Programs, CFDA 93.279) effective September 1, 2025, through August 31, 2027. The award funds research investigating how substance abuse impacts antibody response in people living with HIV (PLWH), with particular focus on individuals who use substances (PWUS). The research team will conduct immune profiling of antibody...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded University of California, San Diego $1,573,958 under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning August 1, 2025, through April 30, 2030. This Project Grant supports a hybrid Type I implementation trial titled "Breaking Barriers: Innovating HIV Elimination with Social Network Strategies and Routine Substance Use Screening." The study delivers two primary interventions: (1)...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $6.99 million to the University of California, San Francisco under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct an in vivo imaging and post-mortem research study examining the effects of methamphetamine (MA) use on immune dysfunction and HIV-1 reservoir transcription among people with HIV on antiretroviral therapy (ART). The project, initiated July 15, 2025, and extending through...
- This $375,000 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the impact of a status-neutral, person-centric intervention called the "Blue Shed" on HIV transmission and outcomes among people who inject drugs (PWID) in New Delhi, India. The project has three key objectives: Assess the direct impact of the Blue Shed intervention on HIV incidence, viral suppression, and mortality among PWID...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded University of California, Irvine a $1,084,701 Project Grant on July 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the Data Mining and Functional Validation Single-Cell Opioid Responses in Context of HIV (DMFV-SCORCH) project through March 31, 2030. This interdisciplinary initiative aims to uncover multi-scale dysregulations resulting from HIV infection and opioid use disorder...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $804,728 to the Regents of the University of California at Riverside under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a five-year research project spanning June 1, 2025 through April 30, 2030. This Project Grant will fund research investigating the interaction between methamphetamine use and human immunodeficiency virus (HIV) persistence, specifically examining the role of the...
- Federal Grant Award Summary Drexel University received a $501,606 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on hormonal and behavioral dysregulation following exposure to antiretrovirals and chronic cocaine use. The award, effective April 1, 2026 through January 31, 2031, supports preclinical research utilizing the ECOHIV mouse model to investigate interactions between HIV treatment...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $198,854 to the University of California, San Diego under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal study examining trajectories of social isolation and loneliness among older adults living with HIV (Human Immunodeficiency Virus) who use methamphetamine. The two-year project, initiated August 1, 2025 and concluding July 31, 2027, will deliver research services including...
HIV COMPLEX CAUSAL MODELING: GUT MICROBIOME, DRUG USE, AND IMMUNE RESPONSES - PROJECT SUMMARY/ABSTRACT HUMAN IMMUNODEFICIENCY VIRUS (HIV) ACQUISITION OFTEN CO-OCCURS WITH DRUG USE DISORDERS (DUD), PARTICULARLY IN THE CONTEXT OF INJECTED DRUG USE. INDIVIDUALS WITH DUD OR THOSE LIVING WITH HIV/AIDS HAVE BEEN FOUND TO COMMONLY EXPERIENCE CHANGES IN THE BALANCE OF GUT MICROBIOTA (GM) IN THEIR GASTROINTESTINAL TRACT. THE GUT, WHICH IS CONSIDERED THE BODY'S LARGEST IMMUNE ORGAN, HARBORS TRILLIONS OF MICROORGANISMS THAT INFLUENCE HOW OUR BODY RESPONDS TO NEUROLOGICAL AND IMMUNE CHALLENGES OR INFLAMMATION. THUS, DUD, HIV, GM, AND IMMUNE RESPONSES FORM A COMPLEX INTERPLAY, INFLUENCING EACH OTHER. TO ELUCIDATE THE CAUSAL RELATIONSHIP OF HIV ACQUISITION, WE WILL LEVERAGE GENOME-WIDE ASSOCIATION STUDIES (GWAS) SUMMARY STATISTICS AND EXISTING DATASETS. OUR PRIMARY ANALYTICAL STRATEGY INVOLVES EMPLOYING MENDELIAN RANDOMIZATION (MR) COMBINED WITH MEDIATION ANALYSIS. UTILIZING MR ANALYSIS, WHICH RELIES ON GWAS SUMMARY STATISTICS, WE WILL DEPLOY STATIC GWAS-IDENTIFIED GENETIC MARKERS AS INSTRUMENTAL VARIABLES TO ADDRESS CONFOUNDING FACTORS WHILE INFERRING CAUSAL EFFECTS. WE WILL EXAMINE FOUR DISTINCT DUDS, INCLUDING USE DISORDERS OF CANNABIS, COCAINE, TOBACCO, AND OPIOIDS. OUR INVESTIGATION WILL ANALYZE A LARGE-SCALE HUMAN GM GWAS, GWAS OF TARGET IMMUNE-RELATED BIOMARKERS, AND OUR ONGOING HIV GWAS. WITHIN THE MR FRAMEWORK, OUR OUTCOME TRAIT IS HIV ACQUISITION, AND DUDS ARE EXPOSURE VARIABLES. THROUGH UNIVARIATE MR AND MULTIVARIATE MR, WE AIM TO IDENTIFY DRUG-SPECIFIC CAUSAL EFFECTS ON HIV RISK AND IMMUNE RESPONSES. WE WILL ALSO INVESTIGATE GENETIC CORRELATIONS AMONG THESE TRAITS. FURTHERMORE, WE WILL INFER THE CAUSAL MEDIATION RELATIONSHIP AMONG DUD, GM, AND IMMUNE RESPONSES IN HIV RISK, PROVIDING INSIGHTS THROUGH THE ASSESSMENT OF CAUSALITY AND MEDIATION EFFECTS. IN SUMMARY, FINDING CAUSAL EFFECTS BETWEEN DUD AND HIV ACQUISITION IS ESSENTIAL FOR DESIGNING EFFECTIVE PREVENTION AND INTERVENTION STRATEGIES, GUIDING PUBLIC HEALTH POLICIES, UNDERSTANDING THE MECHANISMS INVOLVED, AND ULTIMATELY REDUCING THE BURDEN OF HIV IN POPULATIONS AFFECTED BY DRUG USE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $163.6k | 8/1/25 | ||
| Not listed | $196.4k | 7/26/24 |